Neuro2Go offers a convenient way to talk to a board-certified neurologist, who can provide an At-Home Alzheimer’s Risk Test, to assess the genetic risk of cognitive decline due to Alzheimer’s disease. The test uses a comprehensive genetic analysis for the risk of Alzheimer’s disease from a simple saliva sample. Neuro2Go is a division of First …
Jeffrey Gelblum, MD, a board-certified neurologist with First Choice Neurology and Neuro2Go, the nation’s largest neurology practice, treated the first patient in Florida with Biogen’s Aduhelm (aducanumab), an infusion treatment for early-stage Alzheimer’s patients. Aduhelm decreases amyloid plaque in the brain, which is a marker for Alzheimer’s disease. Florida’s first Aduhelm patient is a middle-aged …
The First Florida Patient to Receive Biogen’s Aduhelm for Alzheimer’s Disease Read More »
If you or a loved one is suffering from memory loss, a new FDA-approved treatment may be just around the corner for Alzheimer’s disease. Could an amyloid-targeting therapy finally be poised for approval? For more than a quarter-century, researchers have targeted amyloid, a protein that clogs the brains of many Alzheimer’s patients. It was first …